MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, announced an investment of more than €300 million into a new Bioprocessing Production Center in Daejeon, South Korea.
The new site is the largest investment by the company’s Life Science business sector in Asia-Pacific to date and is expected to create approximately 300 additional jobs by the end of 2028.
Free access provides up to 10 articles
Subscription options start at $5 per month
which is less than a Starbucks coffee!